NASDAQ:XLO Xilio Therapeutics (XLO) Stock Price, News & Analysis $9.13 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$9.16 +0.03 (+0.38%) As of 09/18/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Xilio Therapeutics Stock (NASDAQ:XLO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xilio Therapeutics alerts:Sign Up Key Stats Today's Range$8.94▼$9.6750-Day Range$8.31▼$9.5052-Week Range$6.47▼$12.74Volume22,937 shsAverage Volume10,281 shsMarket Capitalization$60.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for the treatment of cancer. The company’s approach is designed to activate therapeutic agents selectively within the tumor microenvironment, with the goal of stimulating an immune response against cancer while reducing exposure to healthy tissues and the systemic side effects associated with conventional immunotherapies. Xilio’s product candidates are based on its proprietary tumor-activation technology and include engineered cytokines and immune-oncology antibodies. Its development programs have included tumor-activated versions of interleukin-2, interleukin-12 and anti-CTLA-4 therapies. These candidates are being investigated for potential use in solid tumors, both as standalone treatments and in combination with other cancer therapies. Headquartered in Waltham, Massachusetts, Xilio Therapeutics was founded in 2015 and became a publicly traded company on the Nasdaq under the symbol XLO in 2021. The company’s activities are primarily focused on research, clinical development and advancing its pipeline of oncology medicines through clinical testing and potential strategic partnerships.AI Generated. May Contain Errors. Read More Xilio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreXLO MarketRank™: Xilio Therapeutics scored higher than 1% of companies evaluated by MarketBeat, and ranked 893rd out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXilio Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXilio Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Xilio Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Xilio Therapeutics is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xilio Therapeutics is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXilio Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Xilio Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.87% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 39.07, which indicates bearish sentiment.Change versus previous monthShort interest in Xilio Therapeutics has recently decreased by 0.86%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXilio Therapeutics does not currently pay a dividend.Dividend GrowthXilio Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Xilio Therapeutics this week, compared to 1 article on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.45% of the stock of Xilio Therapeutics is held by insiders.Percentage Held by Institutions54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xilio Therapeutics' insider trading history. Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XLO Stock News HeadlinesReviewing Xilio Therapeutics (NASDAQ:XLO) and Rigel Pharmaceuticals (NASDAQ:RIGL)September 20 at 6:28 AM | americanbankingnews.comXilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 PlanSeptember 2, 2026 | quiverquant.comQSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 21 at 1:00 AM | Altimetry (Ad)Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2026 | globenewswire.comXilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesAugust 12, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | markets.businessinsider.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | globenewswire.comXilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal OfficerJune 29, 2026 | finanznachrichten.deSee More Headlines XLO Stock Analysis - Frequently Asked Questions How have XLO shares performed this year? Xilio Therapeutics' stock was trading at $8.9628 at the beginning of 2026. Since then, XLO shares have increased by 1.9% and is now trading at $9.13. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) released its earnings results on Thursday, August, 13th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.26. The business had revenue of $18.69 million for the quarter, compared to the consensus estimate of $12.72 million. Xilio Therapeutics had a negative net margin of 34.06% and a negative trailing twelve-month return on equity of 71.99%. When did Xilio Therapeutics' stock split? Shares of Xilio Therapeutics reverse split on Friday, March 13th 2026.The 1-14 reverse split was announced on Thursday, March 12th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 12th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Xilio Therapeutics IPO? Xilio Therapeutics (XLO) raised $125 million in an IPO on Wednesday, October 20th 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share. Who are Xilio Therapeutics' major shareholders? Xilio Therapeutics' top institutional shareholders include Stonepine Capital Management LLC (3.43%), GSA Capital Partners LLP (0.21%) and BlackRock Inc. (0.13%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Rene Russo, James Samuel Shannon, Christopher James Frankenfield and Kevin M Brennan. View institutional ownership trends. How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xilio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and Atai Beckley (ATAI). Company Calendar Last Earnings8/13/2026Today9/21/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 XLO's financial health is in the Yellow zone, according to TradeSmith. XLO has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XLO CIK1840233 Webwww.xiliotx.com Phone(617) 833-1027FaxN/AEmployees76Year Founded2015Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.04 million Net Margins-34.06% Pretax Margin-34.06% Return on Equity-71.99% Return on Assets-20.43% Debt Debt-to-Equity RatioN/A Current Ratio4.25 Quick Ratio4.25 Sales & Book Value Annual Sales$43.77 million Price / Sales1.37 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book1.25Miscellaneous Outstanding Shares6,580,000Free Float6,090,000Market Cap$60.08 million OptionableNot Optionable Beta-0.14 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:XLO) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XLO Stock Alerts